Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-30
2007-01-30
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S341000, C546S268400, C546S272100, C546S275400, C546S283400
Reexamination Certificate
active
10779532
ABSTRACT:
The present invention provides compounds of formula I:where R1is H, CONH2, T(n)-R, or T(n)-Ar2, n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
REFERENCES:
patent: 4876252 (1989-10-01), Torley et al.
patent: 5356897 (1994-10-01), Oku et al.
patent: 6514977 (2003-02-01), Anantanarayan et al.
patent: WO 98/52940 (1998-11-01), None
patent: WO 00/31063 (2000-06-01), None
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15), May 1999.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thedition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20theEdition, vol. 2, pp. 2050-2057, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Traxler, Protein Tyrosine Kinase inhibitors in cancer treatment, Exp Opin. Ther. Patents, 7(6):751-588, 1997.
Hassan, et al., “Synthesis and Reactions of 5-(D-arabino-tetrahydroxybutyl)-3-(2,3-dihydro-1,3,4-oxadiazole-2-thion-5-yl)-2-methylfuran and 5-(D-arabino-tetrahydroxybutyl)-3-(2-substituted amino-1,3,4-oxadiazol-5-yl)-2-methylfuran”,Carboh. Res.,298:123-126 (1997).
Paul, et al., “Preparation of Sustituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitots”,J. Med. Chem.,36:2716-2725 (1993).
Khisamutdinov, et al., “Some Reactions of 3-phenyl-5-methyl-4-isoxazole-carboxylic acid Hydrazide”,Khim. Farm. Zh.,2(8):35-37 (1968).
Sokolov, et al., “Isoxazole Compounds—(III) Synthesis of Some Isoxazolylazoles”,Zhor. Obshchei Khim.,30:1781-1787 (1960).
Ihle, N., et al., “Preparation of 4-Alkyl-2-[N-(tert-butoxycarbonly)amino]-pyridines by Alkylation, Nucleophilic Addition, and Acylation of 2[N-(tert-butoxycarbonyl)amino]-4-picoline”,J. Org. Chem.,61:4810-4811 (1996).
Baker Christopher
Bemis Guy
Cao Jingrong
Gao Huai
Green Jeremy
Brown Karen E.
Rao Deepak
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of c-Jun N terminal kinases (JNK) and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of c-Jun N terminal kinases (JNK) and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of c-Jun N terminal kinases (JNK) and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3795294